Observational studyCNS drugs2021

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.

Sifat Sharmin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.